Making future options possible1,2

Excellent performance for today's coronary access


(68/68) success post-TAVI coronary access rate1

Preserving coronary access for future needs


risk of future sinus sequestration¶3

Risk of sinus sequestration if (1) prior TAV commissure level above STJ and (2) the distance between TAV and STJ was <2.0mm in each coronary sinus.

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVI experience an implanter can count on, starting with the index procedure.

Designed to host future valve interventions

Preserving future coronary access is a key consideration in valve-in-valve patients3,4

  • SAPIEN 3 valve-first TAVI reduces risks of future sinus sequestration†2
  • SAPIEN 3 valve-first TAVI facilitates favorable coronary access3

Risk of sinus sequestration if (1) prior TAV commissure level above STJ and (2) the distance between TAV and STJ was <2.0mm in each coronary sinus.

The only platform approved and indicated for both TAV-in-TAV and TAV-in-SAV procedures5**

Primary endpoints of death and stroke for SAPIEN 3 valve (Native vs Redo)6

  • No statistical difference in death and stroke between redo SAPIEN 3 TAVI vs. native SAPIEN 3 TAVI at 1 year

** Patients assessed at high-risk for surgical replacement. Edwards Lifesciences SAPIEN 3/Ultra valve Instructions for Use.


1. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972.
2. Tarantini G, et al. Redo-Transcatheter aortic valve implantation using the SAPIEN 3/Ultra transcatheter heart valves – Expert Consensus on Procedural Planning Techniques, The American Journal of Cardiology, 2023
3. Ochiai T, Oakley L, Sekhon N, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13(22):2617-2627. doi:10.1016/j.jcin.2020.09.022.
4. De Backer O, Landes U, Fuchs A, et al. Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography. JACC Cardiovasc Interv. 2020;13(21):2528-2538.
5. Edwards Lifesciences SAPIEN 3/Ultra valve Instructions for Use.
6. Makkar RR, et al. Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study. Lancet. 2023 Aug 31:S0140-6736(23)01636-7.
7. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
8. Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in PARTNER-2 trial. J Am Coll Cardiol. 2020;76(16):1830-1843.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

PP--EU-7520 v1.0